CURRICULUM VITAE DEL PROF. PAOLO PUCCETTI

1. Informazioni personali

Nato l'11 gennaio 1952, ha conseguito la maturità classica nella sessione estiva dell'anno scolastico 1969-70 con la votazione di 60/60. È coniugato con due figli.

2. Istruzione e formazione

- Iscritto alla Facoltà di Farmacia dell'Università degli Studi di Perugia, si è laureato nel luglio 1974 con la votazione di 110/110 e lode discutendo una tesi sperimentale elaborata presso l'Istituto di Farmacologia.

- Iscritto alla Facoltà di Medicina e Chirurgia della medesima Università, si è laureato nell'ottobre 1982 con la votazione di 110/110 e lode.

3. Esperienze professionali

- Dal novembre 1974 al luglio 1980 è stato titolare di un assegno di studio di formazione scientifica e didattica presso l'Istituto di Farmacologia della suddetta Università.

- Negli anni 1976-77 ha usufruito di detto assegno presso il *Laboratory of Immunodiagnosis, National Cancer Institute, National Institutes of Health*, in Bethesda, Maryland, USA.

- Dall'agosto 1980 al marzo 1988 è stato ricercatore confermato presso la Cattedra di Farmacologia e Farmacognosia della Facoltà di Farmacia dell'Università degli Studi di Perugia.

- Dall'anno accademico 1987-88 e fino al 31 ottobre 1994 è stato professore associato di Chemioterapia presso la Facoltà di Farmacia dell'Università degli Studi di Perugia.

- Negli anni accademici 1990-91 e 1991-92 gli è stata affidata la supplenza per l'insegnamento di "Farmacologia" nel corso di laurea in Odontoiatria e Protesi Dentaria presso la Facoltà di Medicina e Chirurgia dell'Università di Roma - Tor Vergata.

- Dal 1° novembre 1994 al 31 ottobre 1997 è stato professore straordinario di "Chemioterapia" presso la la Facoltà di Medicina e Chirurgia dell'Università di Roma - Tor Vergata.

- Nell'anno accademico 1994-95 ha avuto l'incarico per l'insegnamento di "Farmacologia e Farmacognosia II" nel corso di laurea in Farmacia presso la Facoltà di Farmacia dell'Università di Perugia.

- Negli anni accademici 1995-96 e 1996-97 ha avuto l'incarico per l'insegnamento di "Farmacologia e Farmacognosia I" nel corso di laurea in Farmacia presso la Facoltà di Farmacia dell'Università di Perugia.

- Dal 1° novembre 1997 è stato chiamato a ricoprire mediante trasferimento un posto di professore universitario di ruolo di I fascia presso la Facoltà di Farmacia dell'Università degli Studi di Perugia per il settore disciplinare E07X, ed è diventato titolare dell'insegnamento di "Farmacologia

Generale" per il corso di Laurea in Farmacia.

- Nell'anno accademico 1997-98 ha avuto l'incarico per l'insegnamento di "Saggi e Dosaggi Farmacologici" nel corso di laurea di Chimica e Tecnologia Farmaceutiche.

- Negli anni accademici 1999-2000 e 2000-01 ha tenuto l'incarico per l'insegnamento di "Farmacologia e Farmacognosia III" nel corso di laurea in Farmacia.

- Dall'anno accademico 2000-01 ha anche tenuto l'incarico per l'insegnamento di "Farmacologia e Farmacoterapia" nel corso di laurea in Specialistica Farmacia, nei diversi ordinamenti.

- Attualmente è inquadrato dal MIUR come PROFESSORE ORDINARIO – Settore: BIO/14 FARMACOLOGIA, Settore concorsuale: 05/G1, Università degli Studi di PERUGIA, Dipartimento di MEDICINA SPERIMENTALE – ed è titolare degli insegnamenti di "Farmacocinetica, Farmacologia Generale e Farmacognosia" e di "Farmacologia, Farmacoterapia e Chemioterapia" per il corso di Laurea Magistrale in Farmacia.

- È stato lungamente titolare di insegnamenti nel corso di Laurea Magistrale in Biotecnologie Farmaceutiche ed in Scuole di Specializzazione.

4. Capacità e competenze gestionali

SOCIETÀ SCIENTIFICHE, ATTIVITÀ EDITORIALE E BREVETTUALE

- Società Italiana di Farmacologia
  Collegio Nazionale dei Farmacologi Universitari
  Associazione Italiana di Immunofarmacologia
  Società Italiana di Chemioterapia
  Società Italiana di Cancerologia
  Società Italiana di Biologia Sperimentale
  American Association of Immunologists
  American Institute of Biological Sciences
  European Association for Cancer Reasearch
  International Society of Immunopharmacology

- È *Section* e/o *Field Editor* di riviste a diffusione internazionale, ed è *Acknowledged Reviewer* per oltre 10 riviste con *impact factor* superiore a 5. In particolare, è membro dell'*Editorial Board* di prestigiose pubblicazioni, tra cui *The Journal of Immunology* (organo ufficiale di *The American Association of Immunologists*, in cui ha anche ricoperto il ruolo di *Associate Editor*), *Amino Acids*, *ISRN Immunology*, e *International Journal of Tryptophan Research*.

- È stato titolare di numerosi progetti co-finanziati biennali (1999, 2001, 2003, 2005, 2007, 2009) o finanziati da Agenzie nazionali (inclusa l'Associazione per la Ricerca sul Cancro – Progetti triennali degli ultimi 10 anni: *Tryptophan catabolism in experimental antitumor immunotherapy*, 2005; *Orchestrating tryptophan catabolism in experimental neoplasia*, 2008; *Tryptophan-degrading enzymes in neoplasia: Who does what*, 2012) ed internazionali (inclusa la *Juvenile Diabetes Research Foundation, USA*).

- È coinventore di brevetti, tra i quali:

- *Becchetti, E., R. Calafiore, M. Calvitti, F. Fallarino, G. Luca, C. Nastruzzi, and P. Puccetti. Hydrogel-based microcapsules manufacture for prevention and treatment of type I diabetes mellitus includes production of Sertoli cells in saline solution of ultrapure sodium alginate, and aspiration and introduction into needle-type element. In: Univ Perugia; Gh Care Inc Dba Altucell Inc;*
- *Calafiore R; Luca G; Calvitti M; Becchetti E; Puccetti P; Fallarino F; Nastruzzi C. Microencapsulation process of sertoli cells, microcapsules obtained and their use for prevention and cure of type i diabetes mellitus. US 2011/0250280 A1*
- *Francesca Fallarino, Ursula Grohmann, Paolo Puccetti. Use of l-kynurenine and derivatives thereof for the prevention and treatment of diabetes mellitus type 1. WO 2010041288 A1.*
- *Bistoni, F., P. Puccetti, and L. Romani. Use of L-kynurenine amino acid and its derivative, both natural and synthetic, in medical field for the preparation of a medicament for the treatment of chronic inflammatory pathologies such as chronic granulomatous disease and allergy. In: Puccetti P; Bistoni F; Romani L. WIPO Patent Application WO/2009/040849 Kind Code: A1.*
- *Donti, E., F. Fallarino, I. Pirisinu, P. Puccetti, R. Romani, G. Rosi, and G. Bistoni. Isolating pluripotent stem cell from amniotic liquid heterogeneous cell mixture involves culturing cell from the fresh liquid; selecting by optical microscope observation adhered cell culture; isolating; carrying out passage number in vitro. In: Univ Perugia. WO Patent 2,012,014,247.*

PARTECIPAZIONE AD ORGANI COLLEGIALI

- È attualmente membro del Nucleo di Valutazione dell'Università degli Studi di Perugia.

- È attualmente Presidente del Comitato Universitario di Bioetica dell'Università degli Studi di Perugia.

- È attualmente membro del Consiglio del Dipartimento di Medicina Sperimentale, in cui è anche Responsabile della sezione di Farmacologia.

- È stato membro della Commissione Spin-off d'Ateneo.

- È stato membro della Giunta della Facoltà di Farmacia, in cui ha anche ricoperto il ruolo di Vicepreside (dal 2003 al 2013).

5. Qualificazione scientifica e culturale

- In oltre 30 anni di ricerca nel campo dell'immunoterapia anti-infettiva ed antitumorale, ivi inclusa l'attività di ricerca presso il Laboratorio di Immunodiagnosi diretto dal Dr. Herberman presso l'NIH (USA), il prof. Puccetti è autore di oltre 200 articoli che appaiono in MEDLINE, fonte:

http://www.ncbi.nlm.nih.gov/pubmed/

- Pubblicazioni di eccellenza nel periodo 2002-2013 includono 10 articoli in riviste *Nature*, di cui alcune con oltre 500 citazioni nel periodo suddetto (fonti, *WEB OF SCIENCE & GOOGLE SCHOLAR*)

Citation indices

	All	Since 2009
Citations	15515	5886
h-index	67	40
i10-index	161	88



Dati bibiometrici sulle pubblicazioni

Banca Dati AIRC per il periodo 2007-2012

Lavori Totali con *Impact Factor* (IF) = 14; IF su Lavori Totali = 223,59;
IF Medio su Lavori Totali = 16.

Banca Dati *Google Scholar*

http://scholar.google.com/citations?hl=en&user=950IJKUAAAAJ&view_op=list_works&is_public_preview=1

Il Prof. Puccetti figura al 17° posto per citazioni [15.515 al 3/2/2014] nella graduatoria internazionale dei farmacologi [*label:pharmacology*].

Banca Dati *VIA-Academy*

http://www.topitalianscientists.org/Top_italian_scientists_VIA-Academy.aspx

Il prof. Puccetti figura al 59° posto nell'elenco degli scienziati italiani, residenti in Italia o all'estero, a maggiore impatto a livello internazionale in ogni campo della scienza (***Top Italian Scientists della VIA-Academy***) [al 3/2/2014].

H-index, 67 (fonte, *Top Italian Scientists*)

Rank	Academic	H-index	Nation	Area	Italian_Institution	note
59	Paolo Puccetti	67	Italy	pharmacology - medicine	Perugia	Verified Google Scholar MyCitations

Elenco delle pubblicazioni

1. Zelante, T., *et al.* Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. *Immunity* **39**, 372-385 (2013).
2. Volpi, C., *et al.* High doses of CpG oligodeoxynucleotides stimulate a tolerogenic TLR9-TRIF pathway. *Nat Commun* **4**, 1852 (2013).
3. Iannitti, R.G., *et al.* Th17/Treg imbalance in murine cystic fibrosis is linked to indoleamine 2,3-dioxygenase deficiency but corrected by kynurenines. *Am J Respir Crit Care Med* **187**, 609-620 (2013).
4. Volpi, C., *et al.* A GpC-rich oligonucleotide acts on plasmacytoid dendritic cells to promote immune suppression. *J Immunol* **189**, 2283-2289 (2012).
5. Iorio, A., Puccetti, P. & Makris, M. Clotting factor concentrate switching and inhibitor development in hemophilia A. *Blood* **120**, 720-727 (2012).

6. Pallotta, M.T., *et al.* Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. *Nat Immunol* **12**, 870-878 (2011).
7. Matteoli, G., *et al.* Gut CD103+ dendritic cells express indoleamine 2,3-dioxygenase which influences T regulatory/T effector cell balance and oral tolerance induction. *Gut* **59**, 595-604 (2010).
8. Luca, G., *et al.* Xenograft of microencapsulated sertoli cells reverses T1DM in NOD mice by inducing neogenesis of beta-cells. *Transplantation* **90**, 1352-1357 (2010).
9. Fallarino, F., *et al.* Metabotropic glutamate receptor-4 modulates adaptive immunity and restrains neuroinflammation. *Nat Med* **16**, 897-902 (2010).
10. De Luca, A., *et al.* IL-22 defines a novel immune pathway of antifungal resistance. *Mucosal Immunol* **3**, 361-373 (2010).
11. Zelante, T., Fallarino, F., Bistoni, F., Puccetti, P. & Romani, L. Indoleamine 2,3-dioxygenase in infection: the paradox of an evasive strategy that benefits the host. *Microbes Infect* **11**, 133-141 (2009).
12. Segal, B.H., Romani, L. & Puccetti, P. Chronic granulomatous disease. *Cell Mol Life Sci* **66**, 553-558 (2009).
13. Romani, L., *et al.* Indoleamine 2,3-dioxygenase (IDO) in inflammation and allergy to Aspergillus. *Med Mycol* **47 Suppl 1**, S154-161 (2009).
14. Fallarino, F., *et al.* IDO mediates TLR9-driven protection from experimental autoimmune diabetes. *J Immunol* **183**, 6303-6312 (2009).
15. Fallarino, F., *et al.* Therapy of experimental type 1 diabetes by isolated Sertoli cell xenografts alone. *J Exp Med* **206**, 2511-2526 (2009).
16. Bonifazi, P., *et al.* Balancing inflammation and tolerance in vivo through dendritic cells by the commensal Candida albicans. *Mucosal Immunol* **2**, 362-374 (2009).
17. Belladonna, M.L., Orabona, C., Grohmann, U. & Puccetti, P. TGF-beta and kynurenines as the key to infectious tolerance. *Trends Mol Med* **15**, 41-49 (2009).
18. Wakashin, H., *et al.* IL-23 and Th17 cells enhance Th2-cell-mediated eosinophilic airway inflammation in mice. *Am J Respir Crit Care Med* **178**, 1023-1032 (2008).
19. Romani, L., Zelante, T., De Luca, A., Fallarino, F. & Puccetti, P. IL-17 and therapeutic kynurenines in pathogenic inflammation to fungi. *J Immunol* **180**, 5157-5162 (2008).
20. Romani, L., *et al.* Indoleamine 2,3-dioxygenase (IDO) in inflammation and allergy to Aspergillus. *Med Mycol*, 1-8 (2008).
21. Romani, L. & Puccetti, P. Immune regulation and tolerance to fungi in the lungs and skin. *Chem Immunol Allergy* **94**, 124-137 (2008).
22. Romani, L., *et al.* Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease. *Nature* **451**, 211-215 (2008).
23. Puccetti, P. & Fallarino, F. Generation of T cell regulatory activity by plasmacytoid dendritic cells and tryptophan catabolism. *Blood Cells Mol Dis* **40**, 101-105 (2008).
24. Orabona, C., *et al.* SOCS3 drives proteasomal degradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis. *Proc Natl Acad Sci U S A* **105**, 20828-20833 (2008).
25. Bozza, S., *et al.* Lack of Toll IL-1R8 exacerbates Th17 cell responses in fungal infection. *J Immunol* **180**, 4022-4031 (2008).
26. Belladonna, M.L., *et al.* Cutting edge: Autocrine TGF-beta sustains default tolerogenesis by IDO-competent dendritic cells. *J Immunol* **181**, 5194-5198 (2008).
27. Zelante, T., *et al.* Receptors and pathways in innate antifungal immunity: the implication for tolerance and immunity to fungi. *Adv Exp Med Biol* **590**, 209-221 (2007).
28. Zelante, T., *et al.* IL-23 and the Th17 pathway promote inflammation and impair antifungal immune resistance. *Eur J Immunol* **37**, 2695-2706 (2007).
29. Romani, L. & Puccetti, P. Controlling pathogenic inflammation to fungi. *Expert Rev Anti Infect Ther* **5**, 1007-1017 (2007).
30. Romani, L., *et al.* Thymosin alpha1: an endogenous regulator of inflammation, immunity, and tolerance. *Ann N Y Acad Sci* **1112**, 326-338 (2007).
31. Puccetti, P. & Grohmann, U. IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-kappaB activation. *Nat Rev Immunol* **7**, 817-823 (2007).
32. Puccetti, P. & Fallarino, F. Generation of T cell regulatory activity by plasmacytoid dendritic cells and tryptophan catabolism. *Blood Cells Mol Dis* (2007).
33. Puccetti, P. On watching the watchers: IDO and type I/II IFN. *Eur J Immunol* **37**, 876-879 (2007).
34. Grohmann, U., *et al.* Reverse signaling through GITR ligand enables dexamethasone to activate IDO in allergy. *Nat Med* **13**, 579-586 (2007).
35. Fallarino, F., Gizzi, S., Mosci, P., Grohmann, U. & Puccetti, P. Tryptophan catabolism in IDO+ plasmacytoid dendritic cells. *Curr Drug Metab* **8**, 209-216 (2007).
36. De Luca, A., *et al.* Functional yet balanced reactivity to Candida albicans requires TRIF, MyD88, and IDO-dependent inhibition of Rorc. *J Immunol* **179**, 5999-6008 (2007).
37. Belladonna, M.L., *et al.* Immunosuppression via tryptophan catabolism: the role of kynurenine pathway enzymes. *Transplantation* **84**, S17-20 (2007).

38. Romani, L. & Puccetti, P. Protective tolerance to fungi: the role of IL-10 and tryptophan catabolism. *Trends Microbiol* **14**, 183-189 (2006).
39. Romani, L., *et al.* Thymosin alpha1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance. *Blood* **108**, 2265-2274 (2006).
40. Orabona, C., *et al.* Toward the identification of a tolerogenic signature in IDO-competent dendritic cells. *Blood* **107**, 2846-2854 (2006).
41. Montagnoli, C., *et al.* Immunity and tolerance to Aspergillus involve functionally distinct regulatory T cells and tryptophan catabolism. *J Immunol* **176**, 1712-1723 (2006).
42. Fallarino, F. & Puccetti, P. Toll-like receptor 9-mediated induction of the immunosuppressive pathway of tryptophan catabolism. *Eur J Immunol* **36**, 8-11 (2006).
43. Fallarino, F., *et al.* The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor {zeta}-chain and induce a regulatory phenotype in naive T cells. *J Immunol* **176**, 6752-6761 (2006).
44. Fallarino, F., *et al.* Tryptophan catabolism generates autoimmune-preventive regulatory T cells. *Transpl Immunol* **17**, 58-60 (2006).
45. Belladonna, M.L., *et al.* IL-23 neutralization protects mice from Gram-negative endotoxic shock. *Cytokine* **34**, 161-169 (2006).
46. Belladonna, M.L., *et al.* Kynurenine pathway enzymes in dendritic cells initiate tolerogenesis in the absence of functional IDO. *J Immunol* **177**, 130-137 (2006).
47. Vacca, C., *et al.* CD40 ligation prevents onset of tolerogenic properties in human dendritic cells treated with CTLA-4-Ig. *Microbes Infect* **7**, 1040-1048 (2005).
48. Orabona, C., *et al.* Enhanced tryptophan catabolism in the absence of the molecular adapter DAP12. *Eur J Immunol* **35**, 3111-3118 (2005).
49. Orabona, C., *et al.* Cutting edge: silencing suppressor of cytokine signaling 3 expression in dendritic cells turns CD28-Ig from immune adjuvant to suppressant. *J Immunol* **174**, 6582-6586 (2005).
50. Fallarino, F., *et al.* Ligand and cytokine dependence of the immunosuppressive pathway of tryptophan catabolism in plasmacytoid dendritic cells. *Int Immunol* **17**, 1429-1438 (2005).
51. Bozza, S., *et al.* A crucial role for tryptophan catabolism at the host/Candida albicans interface. *J Immunol* **174**, 2910-2918 (2005).
52. Romani, L., *et al.* The exploitation of distinct recognition receptors in dendritic cells determines the full range of host immune relationships with Candida albicans. *Int Immunol* **16**, 149-161 (2004).
53. Orabona, C., *et al.* CD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86. *Nat Immunol* **5**, 1134-1142 (2004).
54. Fallarino, F., *et al.* CTLA-4-Ig activates forkhead transcription factors and protects dendritic cells from oxidative stress in nonobese diabetic mice. *J Exp Med* **200**, 1051-1062 (2004).
55. Fallarino, F., *et al.* Murine plasmacytoid dendritic cells initiate the immunosuppressive pathway of tryptophan catabolism in response to CD200 receptor engagement. *J Immunol* **173**, 3748-3754 (2004).
56. Romani, L., Bistoni, F. & Puccetti, P. Adaptation of Candida albicans to the host environment: the role of morphogenesis in virulence and survival in mammalian hosts. *Curr Opin Microbiol* **6**, 338-343 (2003).
57. Grohmann, U. & Puccetti, P. CTLA-4, T helper lymphocytes and dendritic cells: an internal perspective of T-cell homeostasis. *Trends Mol Med* **9**, 133-135 (2003).
58. Grohmann, U., Fallarino, F. & Puccetti, P. Tolerance, DCs and tryptophan: much ado about IDO. *Trends Immunol* **24**, 242-248 (2003).
59. Grohmann, U., *et al.* Tryptophan catabolism in nonobese diabetic mice. *Adv Exp Med Biol* **527**, 47-54 (2003).
60. Grohmann, U., *et al.* A defect in tryptophan catabolism impairs tolerance in nonobese diabetic mice. *J Exp Med* **198**, 153-160 (2003).
61. Grohmann, U., *et al.* Functional plasticity of dendritic cell subsets as mediated by CD40 versus B7 activation. *J Immunol* **171**, 2581-2587 (2003).
62. Fallarino, F., *et al.* T cell apoptosis by kynurenines. *Adv Exp Med Biol* **527**, 183-190 (2003).
63. Fallarino, F., *et al.* Modulation of tryptophan catabolism by regulatory T cells. *Nat Immunol* **4**, 1206-1212 (2003).
64. Romani, L., Bistoni, F. & Puccetti, P. Fungi, dendritic cells and receptors: a host perspective of fungal virulence. *Trends Microbiol* **10**, 508-514 (2002).
65. Puccetti, P., Belladonna, M.L. & Grohmann, U. Effects of IL-12 and IL-23 on antigen-presenting cells at the interface between innate and adaptive immunity. *Crit Rev Immunol* **22**, 373-390 (2002).
66. Grohmann, U. & Puccetti, P. The immunosuppressive activity of proinflammatory cytokines in experimental models: potential for therapeutic intervention in autoimmunity. *Curr Drug Targets Inflamm Allergy* **1**, 77-87 (2002).
67. Grohmann, U., *et al.* CTLA-4-Ig regulates tryptophan catabolism in vivo. *Nat Immunol* **3**, 1097-1101 (2002).
68. Fallarino, F., *et al.* Functional expression of indoleamine 2,3-dioxygenase by murine CD8 alpha(+) dendritic cells. *Int Immunol* **14**, 65-68 (2002).
69. Fallarino, F., *et al.* T cell apoptosis by tryptophan catabolism. *Cell Death Differ* **9**, 1069-1077 (2002).

70. Fallarino, F., *et al.* CD40 ligand and CTLA-4 are reciprocally regulated in the Th1 cell proliferative response sustained by CD8(+) dendritic cells. *J Immunol* **169**, 1182-1188 (2002).
71. Belladonna, M.L., *et al.* IL-23 and IL-12 have overlapping, but distinct, effects on murine dendritic cells. *J Immunol* **168**, 5448-5454 (2002).
72. Periti, P., Romani, L., Bonmassar, E. & Puccetti, P. Drugs and the immune system: the emerging era of immunopharmacology. *Trends Immunol* **22**, 178-180 (2001).
73. Grohmann, U., *et al.* CD40 ligation ablates the tolerogenic potential of lymphoid dendritic cells. *J Immunol* **166**, 277-283 (2001).
74. Grohmann, U., *et al.* IL-6 inhibits the tolerogenic function of CD8 alpha+ dendritic cells expressing indoleamine 2,3-dioxygenase. *J Immunol* **167**, 708-714 (2001).
75. Grohmann, U., *et al.* Positive regulatory role of IL-12 in macrophages and modulation by IFN-gamma. *J Immunol* **167**, 221-227 (2001).
76. Grohmann, U., *et al.* IL-9 protects mice from Gram-negative bacterial shock: suppression of TNF-alpha, IL-12, and IFN-gamma, and induction of IL-10. *J Immunol* **164**, 4197-4203 (2000).
77. Grohmann, U., *et al.* IL-12 induces SDS-stable class II alphabeta dimers in murine dendritic cells. *Cytokine* **12**, 401-404 (2000).
78. Grohmann, U., *et al.* IFN-gamma inhibits presentation of a tumor/self peptide by CD8 alpha- dendritic cells via potentiation of the CD8 alpha+ subset. *J Immunol* **165**, 1357-1363 (2000).
79. Giampietri, A., *et al.* Dual effect of IL-4 on resistance to systemic gram-negative infection and production of TNF-alpha. *Cytokine* **12**, 417-421 (2000).
80. Fallarino, F., *et al.* Th1 and Th2 cell clones to a poorly immunogenic tumor antigen initiate CD8+ T cell-dependent tumor eradication in vivo. *J Immunol* **165**, 5495-5501 (2000).
81. Grohmann, U., *et al.* IL-12 acts selectively on CD8 alpha- dendritic cells to enhance presentation of a tumor peptide in vivo. *J Immunol* **163**, 3100-3105 (1999).
82. Grohmann, U., *et al.* Immunogenicity of tumor peptides: importance of peptide length and stability of peptide/MHC class II complex. *Cancer Immunol Immunother* **48**, 195-203 (1999).
83. Bianchi, R., *et al.* Autocrine IL-12 is involved in dendritic cell modulation via CD40 ligation. *J Immunol* **163**, 2517-2521 (1999).
84. Grohmann, U., *et al.* Dendritic cells, interleukin 12, and CD4+ lymphocytes in the initiation of class I-restricted reactivity to a tumor/self peptide. *Crit Rev Immunol* **18**, 87-98 (1998).
85. Grohmann, U., *et al.* IL-12 acts directly on DC to promote nuclear localization of NF-kappaB and primes DC for IL-12 production. *Immunity* **9**, 315-323 (1998).
86. Fallarino, F., Fields, P.E. & Gajewski, T.F. B7-1 engagement of cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28. *J Exp Med* **188**, 205-210 (1998).
87. Belladonna, M.L., *et al.* The role of IL-12 in the induction of an immune response to a tumor/self peptide: prevention and reversion of anergy. *J Chemother* **10**, 157-159 (1998).
88. Romani, L., Puccetti, P. & Bistoni, F. Interleukin-12 in infectious diseases. *Clin Microbiol Rev* **10**, 611-636 (1997).
89. Romani, L., *et al.* Neutrophil production of IL-12 and IL-10 in candidiasis and efficacy of IL-12 therapy in neutropenic mice. *J Immunol* **158**, 5349-5356 (1997).
90. Romani, L., *et al.* An immunoregulatory role for neutrophils in CD4+ T helper subset selection in mice with candidiasis. *J Immunol* **158**, 2356-2362 (1997).
91. Romani, L., Bistoni, F. & Puccetti, P. Initiation of T-helper cell immunity to Candida albicans by IL-12: the role of neutrophils. *Chem Immunol* **68**, 110-135 (1997).
92. Navarra, P., *et al.* Hydroxyurea induces the gene expression and synthesis of proinflammatory cytokines in vivo. *J Pharmacol Exp Ther* **280**, 477-482 (1997).
93. Grohmann, U., *et al.* Circulating levels of IL-10 are critically related to growth and rejection patterns of murine mastocytoma cells. *Cell Immunol* **181**, 109-119 (1997).
94. Grohmann, U., *et al.* Dendritic cells and interleukin 12 as adjuvants for tumor-specific vaccines. *Adv Exp Med Biol* **417**, 579-582 (1997).
95. Grohmann, U., *et al.* A tumor-associated and self antigen peptide presented by dendritic cells may induce T cell anergy in vivo, but IL-12 can prevent or revert the anergic state. *J Immunol* **158**, 3593-3602 (1997).
96. Romani, L., Puccetti, P. & Bistoni, F. Biological role of Th cell subsets in candidiasis. *Chem Immunol* **63**, 115-137 (1996).
97. Romani, L., *et al.* Impaired neutrophil response and CD4+ T helper cell 1 development in interleukin 6-deficient mice infected with Candida albicans. *J Exp Med* **183**, 1345-1355 (1996).
98. Romani, L., Mencacci, A., Cenci, E., Puccetti, P. & Bistoni, F. Neutrophils and the adaptive immune response to Candida albicans. *Res Immunol* **147**, 512-518 (1996).
99. Campanile, F., *et al.* Evidence for tumor necrosis factor alpha as a mediator of the toxicity of a cyclooxygenase inhibitor in Gram-negative sepsis. *Eur J Pharmacol* **307**, 191-199 (1996).

100. Bianchi, R., *et al.* IL-12 is both required and sufficient for initiating T cell reactivity to a class I-restricted tumor peptide (P815AB) following transfer of P815AB-pulsed dendritic cells. *J Immunol* **157**, 1589-1597 (1996).
101. Belladonna, M.L., Fioretti, M.C., Bianchi, R., Puccetti, P. & Grohmann, U. A retroviral peptide encoded by mutated env p15E gene is recognized by specific CD8+ T lymphocytes on drug-treated murine mastocytoma P815. *Int J Immunopharmacol* **18**, 563-576 (1996).
102. Tonnetti, L., *et al.* Interleukin-4 and -10 exacerbate candidiasis in mice. *Eur J Immunol* **25**, 1559-1565 (1995).
103. Spaccapelo, R., *et al.* TGF-beta is important in determining the in vivo patterns of susceptibility or resistance in mice infected with Candida albicans. *J Immunol* **155**, 1349-1360 (1995).
104. Romani, L., Cenci, E., Menacci, A., Bistoni, F. & Puccetti, P. T helper cell dichotomy to Candida albicans: implications for pathology, therapy, and vaccine design. *Immunol Res* **14**, 148-162 (1995).
105. Romani, L., *et al.* IL12 in Candida albicans infections. *Res Immunol* **146**, 532-538 (1995).
106. Puccetti, P., Romani, L. & Bistoni, F. A TH1-TH2-like switch in candidiasis: new perspectives for therapy. *Trends Microbiol* **3**, 237-240 (1995).
107. Navarra, P., Puccetti, P., Riccardi, C. & Preziosi, P. Anticancer drug toxicity via cytokine production: the hydroxyurea paradigm. *Toxicol Lett* **82-83**, 167-171 (1995).
108. Grohmann, U., *et al.* Multiple point mutations in an endogenous retroviral gene confer high immunogenicity on a drug-treated murine tumor. *J Immunol* **154**, 4630-4641 (1995).
109. Grohmann, U., *et al.* CD8+ cell activation to a major mastocytoma rejection antigen, P815AB: requirement for tum- or helper peptides in priming for skin test reactivity to a P815AB-related peptide. *Eur J Immunol* **25**, 2797-2802 (1995).
110. Cenci, E., *et al.* T helper cell type 1 (Th1)- and Th2-like responses are present in mice with gastric candidiasis but protective immunity is associated with Th1 development. *J Infect Dis* **171**, 1279-1288 (1995).
111. Romani, L., *et al.* Tolerance to staphylococcal enterotoxin B initiated Th1 cell differentiation in mice infected with Candida albicans. *Infect Immun* **62**, 4047-4053 (1994).
112. Romani, L., *et al.* Neutralization of IL-10 up-regulates nitric oxide production and protects susceptible mice from challenge with Candida albicans. *J Immunol* **152**, 3514-3521 (1994).
113. Romani, L., *et al.* Interleukin-12 but not interferon-gamma production correlates with induction of T helper type-1 phenotype in murine candidiasis. *Eur J Immunol* **24**, 909-915 (1994).
114. Romani, L., *et al.* IL-12 is both required and prognostic in vivo for T helper type 1 differentiation in murine candidiasis. *J Immunol* **153**, 5167-5175 (1994).
115. Puccetti, P., *et al.* Cure of murine candidiasis by recombinant soluble interleukin-4 receptor. *J Infect Dis* **169**, 1325-1331 (1994).
116. Puccetti, P., *et al.* Use of a skin test assay to determine tumor-specific CD8+ T cell reactivity. *Eur J Immunol* **24**, 1446-1452 (1994).
117. Grohmann, U., *et al.* Endogenous retroviral gp70 genes of the murine lymphoma L5178Y: analysis of restriction fragment polymorphism upon induction of drug-mediated immunogenicity. *Viral Immunol* **7**, 155-167 (1994).
118. Fukazawa, Y., *et al.* Mechanisms of cell-mediated immunity in fungal infection. *J Med Vet Mycol* **32 Suppl 1**, 123-131 (1994).
119. Fioretti, M.C., Grohmann, U. & Puccetti, P. Cytokines and tumours: problems and perspectives. *Pharmacol Res* **29**, 111-119 (1994).
120. Romani, L., *et al.* Natural killer cells do not play a dominant role in CD4+ subset differentiation in Candida albicans-infected mice. *Infect Immun* **61**, 3769-3774 (1993).
121. Romani, L., *et al.* CD4+ subset expression in murine candidiasis. Th responses correlate directly with genetically determined susceptibility or vaccine-induced resistance. *J Immunol* **150**, 925-931 (1993).
122. Grohmann, U., *et al.* Immunogenic properties of retroviral protein P15E from drug-treated murine mastocytoma P815. *Int J Cancer* **55**, 344-350 (1993).
123. Grohmann, U., Binaglia, L., Puccetti, P. & Fioretti, M.C. Cell-mediated immunity to chemically xenogenized tumors--VI. The effect of cell treatment with retroviral env antisense oligonucleotides. *Int J Immunopharmacol* **15**, 567-572 (1993).
124. Cenci, E., *et al.* Interleukin-4 and interleukin-10 inhibit nitric oxide-dependent macrophage killing of Candida albicans. *Eur J Immunol* **23**, 1034-1038 (1993).
125. Campanile, F., *et al.* Accelerated hematopoietic recovery and protective effect of the cyclooxygenase inhibitor indomethacin in bacterial infection of neutropenic mice. *Cell Immunol* **147**, 341-352 (1993).
126. Bistoni, F., *et al.* Mucosal and systemic T helper cell function after intragastric colonization of adult mice with Candida albicans. *J Infect Dis* **168**, 1449-1457 (1993).
127. Romani, L., *et al.* Antigen-specific cytolysis of infected cells in murine candidiasis. *Eur J Epidemiol* **8**, 368-376 (1992).
128. Romani, L., *et al.* Neutralizing antibody to interleukin 4 induces systemic protection and T helper type 1-associated immunity in murine candidiasis. *J Exp Med* **176**, 19-25 (1992).

129. Romani, L., *et al.* Course of primary candidiasis in T cell-depleted mice infected with attenuated variant cells. *J Infect Dis* **166**, 1384-1392 (1992).
130. Romani, L., *et al.* Gamma interferon modifies CD4+ subset expression in murine candidiasis. *Infect Immun* **60**, 4950-4952 (1992).
131. Perito, S., Calabresi, A., Romani, L., Puccetti, P. & Bistoni, F. Involvement of the Th1 subset of CD4+ T cells in acquired immunity to mouse infection with Trypanosoma equiperdum. *Cell Immunol* **143**, 261-271 (1992).
132. Grohmann, U., *et al.* Immunogenic tumor variants induced by drug treatment of the L5178Y lymphoma: search for serologically defined antigens at the clonal level. *Int J Cancer* **52**, 372-377 (1992).
133. Grohmann, U., Binaglia, L., Bianchi, R., Puccetti, P. & Fioretti, M.C. Immune recognition of drug-induced tumor antigens: a study with a nonimmunogenic, revertant clone. *Pharmacol Res* **26 Suppl 2**, 186-187 (1992).
134. Campanile, F., *et al.* Modulation of colony-stimulating activity by interleukin 1 in mice: opposing effects of combined treatment with indomethacin or prostaglandin E2. *Int J Immunopharmacol* **14**, 655-659 (1992).
135. Bianchi, R., Grohmann, U., Fioretti, M.C. & Puccetti, P. Antagonistic effect of IL-2 on DTIC-induced impairment of tumor-specific cell-mediated immunity in vitro. *Pharmacol Res* **26 Suppl 2**, 106-107 (1992).
136. Bianchi, R., Giampietri, A., Campanile, F., Fioretti, M.C. & Puccetti, P. Experimental studies of immunotoxicity of a photosensitizing agent (Photofrin II) in mice. *J Chemother* **4**, 290-296 (1992).
137. Bianchi, R., *et al.* Tumor-specific L3T4+ and Lyt-2+ lymphocytes in mice primed to mutagenized cell variants. *Int J Immunopharmacol* **14**, 915-921 (1992).
138. Bianchi, R., *et al.* O6-methylguanine-DNA methyltransferase activity and induction of novel immunogenicity in murine tumor cells treated with methylating agents. *Cancer Chemother Pharmacol* **29**, 277-282 (1992).
139. Allegrucci, M., *et al.* Molecular and genomic aspects of xenogenizing-alkylating drugs. *Pharmacol Res* **26 Suppl 2**, 24-25 (1992).
140. Romani, L., *et al.* Candida albicans-specific Ly-2+ lymphocytes with cytolytic activity. *Eur J Immunol* **21**, 1567-1570 (1991).
141. Romani, L., *et al.* Th1 and Th2 cytokine secretion patterns in murine candidiasis: association of Th1 responses with acquired resistance. *Infect Immun* **59**, 4647-4654 (1991).
142. Grohmann, U., Romani, L., Binaglia, L., Fioretti, M.C. & Puccetti, P. Intrasplenic immunization for the induction of humoral and cell-mediated immunity to nitrocellulose-bound antigen. *J Immunol Methods* **137**, 9-15 (1991).
143. Cenci, E., *et al.* Macrophage colony-stimulating factor in murine candidiasis: serum and tissue levels during infection and protective effect of exogenous administration. *Infect Immun* **59**, 868-872 (1991).
144. Campanile, F., Binaglia, L., Fioretti, M.C. & Puccetti, P. Modulation of circulating colony-stimulating activity in mice: combined effects of IL-1 and bacterial or indomethacin treatment. *Int J Immunopharmacol* **13**, 955-960 (1991).
145. Romani, L., Grohmann, U., Puccetti, P., Rossi, M.A. & Fioretti, M.C. Cell-mediated immunity to chemically xenogenized tumors. V. Failure of novel antigens to increase the frequency of tumor-specific cytotoxic T cells. *Int J Immunopharmacol* **12**, 743-749 (1990).
146. Grohmann, U., *et al.* Identification and immunogenic properties of an 80-kDa surface antigen on a drug-treated tumor variant: relationship to MuLV gp70. *Eur J Immunol* **20**, 629-636 (1990).
147. Cenci, E., Romani, L., Vecchiarelli, A., Puccetti, P. & Bistoni, F. T cell subsets and IFN-gamma production in resistance to systemic candidosis in immunized mice. *J Immunol* **144**, 4333-4339 (1990).
148. Campanile, F., *et al.* Antibacterial resistance induced by recombinant interleukin 1 in myelosuppressed mice: effect of treatment schedule and correlation with colony-stimulating activity in the bloodstream. *Cell Immunol* **128**, 250-260 (1990).
149. Bianchi, R., *et al.* T-cell subsets, IFN-gamma production and efferent specificity in anti-parental tumor immunity induced by mouse sensitization with xenogenized variant cells. *Int J Cancer* **46**, 653-657 (1990).
150. Vecchiarelli, A., *et al.* Protective immunity induced by low-virulence Candida albicans: cytokine production in the development of the anti-infectious state. *Cell Immunol* **124**, 334-344 (1989).
151. Romani, L., *et al.* Cell-mediated immunity to chemically xenogenized tumors--IV. Production of lymphokine activity by, and in response to, highly immunogenic cells. *Int J Immunopharmacol* **11**, 537-542 (1989).
152. Puccetti, P., Bianchi, R., Romani, L., Cenci, E. & Fioretti, M.C. Delayed-type hypersensitivity to tumor antigens co-expressed with immunogenic determinants induced by xenogenization. *Int J Cancer* **43**, 279-284 (1989).
153. Fuschiotti, P., Fioretti, M.C., Romani, L. & Puccetti, P. Lack of correlation between DNA-methylating activity and appearance of the immunogenic phenotype in clones of a murine lymphoma treated with mutagens. *Cancer Immunol Immunother* **29**, 139-143 (1989).
154. Cenci, E., Romani, L., Vecchiarelli, A., Puccetti, P. & Bistoni, F. Role of L3T4+ lymphocytes in protective immunity to systemic Candida albicans infection in mice. *Infect Immun* **57**, 3581-3587 (1989).
155. Allegrucci, M., Fuschiotti, P., Puccetti, P., Romani, L. & Fioretti, M.C. Changes in the tumorigenic and metastatic properties of murine melanoma cells treated with a triazene derivative. *Clin Exp Metastasis* **7**, 329-341 (1989).

156. Romani, L., *et al.* Cell-mediated immunity to chemically xenogenized tumors. II. Evidence for accessory function and self-antigen presentation by a highly immunogenic tumor variant. *Cell Immunol* **111**, 365-378 (1988).
157. Romani, L., *et al.* Cell-mediated immunity to chemically xenogenized tumors. I. Inhibition by specific antisera and H-2 association of the novel antigens. *Cancer Immunol Immunother* **26**, 48-54 (1988).
158. Grohmann, U., *et al.* Generation of monoclonal antibodies to a chemically xenogenized murine lymphoma. *Pharmacol Res Commun* **20**, 443-444 (1988).
159. Grohmann, U., Puccetti, P., Fioretti, M.C., Mage, M.G. & Romani, L. Cell-mediated immunity to chemically xenogenized tumors--III. Generation of monoclonal antibodies interfering with reactivity to novel antigens. *Int J Immunopharmacol* **10**, 803-809 (1988).
160. Fuschiotti, P., Puccetti, P., Romani, L. & Fioretti, M.C. Regulation of tumor antigen expression by drugs acting as mutagens and/or gene activators. *Pharmacol Res Commun* **20**, 441-442 (1988).
161. Bistoni, F., *et al.* Immunomodulation by a low-virulence, agerminative variant of Candida albicans. Further evidence for macrophage activation as one of the effector mechanisms of nonspecific anti-infectious protection. *J Med Vet Mycol* **26**, 285-299 (1988).
162. Bianchi, R., Romani, L., Puccetti, P. & Fioretti, M.C. Induction of tumor suppression and delayed-type footpad reaction by transfer of lymphocytes sensitized to a xenogenized tumor variant. *Int J Cancer* **42**, 71-75 (1988).
163. Puccetti, P., Romani, L. & Fioretti, M.C. Chemical xenogenization of experimental tumors. *Cancer Metastasis Rev* **6**, 93-111 (1987).
164. Puccetti, P., *et al.* DNA methylating activity in murine lymphoma cells xenogenized by triazene derivatives. *Int J Cancer* **39**, 769-773 (1987).
165. Puccetti, P., *et al.* DNA methylating activity in murine lymphoma cells treated with xenogenizing chemicals. *Cancer Detect Prev Suppl* **1**, 311-316 (1987).
166. Borghi, C., *et al.* Immunopharmacological studies of ribavirin, a broad-spectrum antiviral agent. *Chemioterapia* **6**, 660-663 (1987).
167. Bianchi, R., Romani, L., Puccetti, P. & Fioretti, M.C. Inhibition of murine lymphoma growth by adoptive transfer of lymphocytes sensitized to a xenogenized tumor variant. *Int J Cancer* **40**, 7-11 (1987).
168. Vecchiarelli, A., *et al.* Involvement of host macrophages in the immunoadjuvant activity of amphotericin B in a mouse fungal infection model. *J Antibiot (Tokyo)* **39**, 846-855 (1986).
169. Bistoni, F., *et al.* Evidence for macrophage-mediated protection against lethal Candida albicans infection. *Infect Immun* **51**, 668-674 (1986).
170. Romani, L., Puccetti, P., Fioretti, M.C. & Mage, M.G. Humoral response against murine lymphoma cells xenogenized by drug treatment in vivo. *Int J Cancer* **36**, 225-231 (1985).
171. Romani, L., *et al.* Adoptive immunotherapy of intracerebral murine lymphomas: role of different lymphoid populations. *Int J Cancer* **35**, 659-665 (1985).
172. Campanile, F., Fioretti, M.C., Bonmassar, E. & Puccetti, P. [Antibacterial activity of antibiotics in experimental encephalitis. An indirect approach to the evaluation of the pharmacokinetic pattern]. *G Ital Chemioter* **32**, 225-228 (1985).
173. Campanile, F., Fioretti, M.C., Bonmassar, E. & Puccetti, P. Evaluation of antibacterial activity in experimental meningo-encephalitis in mice. *J Antibiot (Tokyo)* **38**, 1083-1087 (1985).
174. Bistoni, F., *et al.* Immunoadjuvant activity of amphotericin B as displayed in mice infected with Candida albicans. *Antimicrob Agents Chemother* **27**, 625-631 (1985).
175. Nardelli, B., *et al.* Chemical xenogenization of murine lymphoma cells with triazene derivatives: immunotoxicological studies. *Cancer Immunol Immunother* **17**, 213-217 (1984).
176. Marconi, P., Scaringi, L., Tissi, L., Puccetti, P. & Cassone, A. Combined effects of chemotherapy and host antitumor response in a murine histocompatible lymphoma model. *Int J Immunopharmacol* **6**, 217-222 (1984).
177. Campanile, F., Puccetti, P., Angeli, G., Fioretti, M.C. & Bonmassar, E. Experimental studies on mice challenged intracerebrally with Pseudomonas aeruginosa. *Int J Tissue React* **6**, 421-426 (1984).
178. Bistoni, F., Baccarini, M., Puccetti, P., Marconi, P. & Garaci, E. Enhancement of natural killer cell activity in mice by treatment with a thymic factor. *Cancer Immunol Immunother* **17**, 51-55 (1984).
179. Baccarini, M., *et al.* Combined effects of cyclophosphamide and thymostimulin treatment on the in vitro natural killer and candidacidal activity of murine spleen cells. *Int J Tissue React* **6**, 485-492 (1984).
180. Romani, L., Bianchi, R., Puccetti, P. & Fioretti, M.C. Systemic adoptive immunotherapy of a highly immunogenic murine lymphoma growing in the brain. *Int J Cancer* **31**, 477-482 (1983).
181. Puccetti, P., Giampietri, A., Campanile, F., Romani, L. & Fioretti, M.C. Antilymphoma graft responses in the mouse brain: a study of T-dependent functions. *Int J Cancer* **31**, 769-774 (1983).
182. Bistoni, F., *et al.* Correlation between in vivo and in vitro studies of modulation of resistance to experimental Candida albicans infection by cyclophosphamide in mice. *Infect Immun* **40**, 46-55 (1983).
183. Baccarini, M., Blasi, E., Puccetti, P. & Bistoni, F. Phagocytic killing of Candida albicans by different murine effector cells. *Sabouraudia* **21**, 271-286 (1983).
184. Baccarini, M., Bistoni, F., Puccetti, P. & Garaci, E. Natural cell-mediated cytotoxicity against Candida albicans induced by cyclophosphamide: nature of the in vitro cytotoxic effector. *Infect Immun* **42**, 1-9 (1983).

185. Puccetti, P., Romani, L., Taramelli, D., Bonmassar, E. & Fioretti, M.C. Drug-mediated changes of tumour cell immunogenicity and antigenicity. *Int J Tissue React* **4**, 189-199 (1982).
186. Marconi, P., *et al.* Cellular mechanisms underlying the adjuvant activity of Candida albicans in a mouse lymphoma model. *Int J Cancer* **29**, 483-488 (1982).
187. Bistoni, F., Baccarini, M., Blasi, E., Puccetti, P. & Marconi, P. A radiolabel release microassay for phagocytic killing of Candida albicans. *J Immunol Methods* **52**, 369-377 (1982).
188. Giampietri, A., Puccetti, P. & Contessa, A.R. Depression of hepatic biotransformations by chemical immunoadjuvants. *J Immunopharmacol* **3**, 251-264 (1981).
189. Giampietri, A., *et al.* Drug-mediated increase of tumor immunogenicity in vivo for a new approach to experimental cancer immunotherapy. *Cancer Res* **41**, 681-687 (1981).
190. Riccardi, C., Santoni, A., Barlozzari, T., Puccetti, P. & Herberman, R.B. In vivo natural reactivity of mice against tumor cells. *Int J Cancer* **25**, 475-486 (1980).
191. Riccardi, C., *et al.* Combined effects of antineoplastic agents and anti-lymphoma allograft reactions. *Eur J Cancer* **16**, 23-33 (1980).
192. Puccetti, P., Santoni, A., Riccardi, C. & Herberman, R.B. Cytotoxic effector cells with the characteristics of natural killer cells in the lungs of mice. *Int J Cancer* **25**, 153-158 (1980).
193. Herberman, R.B., *et al.* Immunologic reactivity of lymphoid cells in tumors. *Contemp Top Immunobiol* **10**, 61-78 (1980).
194. Santoni, A., Puccetti, P., Riccardi, C., Herberman, R.B. & Bonmassar, E. Augmentation of natural killer activity by pyran copolymer in mice. *Int J Cancer* **24**, 656-661 (1979).
195. Riccardi, C., Puccetti, P., Santoni, A., Herberman, R.B. & Bonmassar, E. Adriamycin-induced antitumor response in lethally irradiated mice. *Immunopharmacology* **1**, 211-220 (1979).
196. Riccardi, C., Puccetti, P., Santoni, A. & Herberman, R.B. Rapid in vivo assay of mouse natural killer cell activity. *J Natl Cancer Inst* **63**, 1041-1045 (1979).
197. Puccetti, P., Santoni, A., Riccardi, C., Holden, H.T. & Herberman, R.B. Activation of mouse macrophages by pyran copolymer and role in augmentation of natural killer activity. *Int J Cancer* **24**, 819-825 (1979).
198. Puccetti, P. & Holden, H.T. Cytolytic and cytostatic anti-tumor activities of macrophages from mice injected with murine sarcoma virus. *Int J Cancer* **23**, 123-132 (1979).
199. Holden, H.T., Varesio, L., Taniyama, T. & Puccetti, P. Functional heterogeneity and T cell-dependent activation of macrophages from murine sarcoma virus (MSV)-induced tumors. *Adv Exp Med Biol* **121B**, 509-520 (1979).
200. Herberman, R.B., *et al.* Natural killer cells: characteristics and regulation of activity. *Immunol Rev* **44**, 43-70 (1979).
201. Riccardi, C., Santoni, A. & Puccetti, P. Effect of immunopharmacologic treatment on anti-tumor immune response in lethally irradiated mice. *Boll Soc Ital Biol Sper* **54**, 1417-1423 (1978).
202. Riccardi, C., *et al.* Growth inhibition of normal or drug-treated lymphoma cells in lethally irradiated mice. *J Natl Cancer Inst* **60**, 1083-1090 (1978).
203. Riccardi, C., Fioretti, M.C., Giampietri, A., Puccetti, P. & Goldin, A. Growth and rejection patterns of murine lymphoma cells antigenically altered following drug treatment in vivo. *Transplantation* **25**, 63-68 (1978).
204. Puccetti, P., Santoni, A. & Riccardi, C. Monitoring of macrophage activation by immunoadjuvants in mice as judged by functional criteria. *Boll Soc Ital Biol Sper* **54**, 1936-1942 (1978).
205. Puccetti, P., Giampietri, A. & Fioretti, M.C. Long-term depression of two primary immune responses induced by a single dose of 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC). *Experientia* **34**, 799-800 (1978).
206. Puccetti, P. & Giampietri, A. Immunopharmacology of pyran copolymer. *Pharmacol Res Commun* **10**, 489-501 (1978).
207. Riccardi, C., Giampietri, A., Puccetti, P., Biancifiori, F. & Fioretti, M.C. Murine leukemia growth inhibition or enhancement following immunization with tumor cells antigenically altered by drug treatment. *Pharmacol Res Commun* **9**, 349-358 (1977).
208. Giampietri, A., Puccetti, P., Circolo, A. & Menconi, E. [Depression of the immune response to lymphoma allotransplant with the use of 5-(3,3-dimethyl-1-triazeno)-imidazol-4-carboxamide (DTIC)]. *Boll Soc Ital Biol Sper* **53**, 922-926 (1977).

Data

04.02.2014

Firma